Biotech
In order to help prepare for the annual meeting of the American Society of Clinical Oncology, better known as ASCO, I've compiled a cheat sheet of significant cancer research abstracts. Use these abstract numbers and titles to search the ASCO Web site on May 15, starting at 9 p.m. EDT. That's when the cancer research group will be posting the full content of the annual meeting research abstracts online. This is the first time ASCO has made research abstracts freely available to everyone in advance of its annual meeting, which runs May 31 through June 3. In years past, of course, many of these abstracts, often containing important and potentially market-moving clinical data, have leaked to well-connected Wall Street investors and traders. That has led to volatile trading in cancer-related biotech stocks in advance of the ASCO meeting. Whether trading volatility ramps up or down this year with abstracts available to everyone remains to be seen. With the list I've put together, however, you should be ready. Before we get to the list of significant abstracts, here are a few notes: The ASCO Web site can be found at www.asco.org, where the annual meeting abstracts will be made available in the Annual Meeting Program Online. As I've warned in the past, ASCO is keeping abstracts for plenary sessions and certain late-breaking presentations under wraps until the start of the meeting. Most importantly, this means that Erbitux results from the FLEX lung cancer study will not be available on May 15. That means ImClone Systems IMCL investors will just have to wait a little while longer.
The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
Surfaxin receives an approvable letter, but the additional delays that accompany it send shares plummeting in premarket trading.
Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.
See who made what calls.
3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA
TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.
Take-Two's latest hit receives a perfect score from industry reviewers.
- Cramer's 'Mad Money' Recap: Mad Money's Rally Playbook
- The Polycarbonate Price Cut
- CalPERS Pushes for Clean House at Standard Pacific
- Investing in China: What You Need to Know
- Coming Week: 'Glimmer of Hope'
- Top Stocks With Insider Buying, Buybacks
- New Solar ETF Helps Spread Sector's Risk
- Feuerstein's Biotech-Stock Mailbag
- Need to Own Energy? Here's How to Do It
- My Company Doesn't Provide Health Insurance (Gulp!)
Sponsored by:

BEAT THE STREET GAME:


